Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.44 |
| ▸ | HMGCR | P04035 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911577 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL157361 | 1.00 | — | — | |
| SCHEMBL1332658 | 1.00 | — | — | |
| SCHEMBL154927 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL15978 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL4879841 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL9234866 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL371425 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL6942814 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL | |
| SCHEMBL18911556 | 1.00 | TSHR (0.50) | TSHRTHRBPTPN7HMGCRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137663-A2 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024129886-A2 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024118979-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-06 | — | — | WO | claimed |
| US-20240175031-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. | 2024-05-30 | — | — | US | claimed |
| EP-4359535-A1 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-05-01 | — | — | EP | claimed |
| EP-4358932-A1 | THICKENING COMPOSITION FOR THICKENING POLAR OR NON-POLAR OILS | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2024-05-01 | — | — | EP | claimed |
| EP-4355429-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4355355-A1 | TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4355430-A1 | TREATMENT OF MST1R RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4355878-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-1991012305-A1 | OIL REMOVAL | NOVO NORDISK A/S (DK) | 1991-08-22 | — | — | WO | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| WO-1990009451-A1 | A PROCESS FOR PRODUCING GLYCOSIDE ESTERS AND COMPOSITIONS COMPRISING GLYCOSIDE ESTERS | NOVO NORDISK A/S (DK) | 1990-08-23 | — | — | WO | claimed |
| EP-0115816-B1 | NEW AMINOGLYCOSIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-08-03 | — | — | EP | claimed |
| US-4725582-A | IMMUNE RESPONSE ENHANCERS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1988-02-16 | — | — | US | claimed |
| US-4554269-A | ANTIVIRAL ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-11-19 | — | — | US | claimed |
| EP-0050856-B1 | NEW PEPTIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-27 | — | — | EP | claimed |
| EP-0115816-A1 | New aminoglycoside derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-15 | — | — | EP | claimed |
| EP-0050856-A2 | New peptide, process for its preparation and pharmaceutical composition containing it | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-05 | — | — | EP | claimed |
| US-4057530-A | STABILIZERS FOR VINYL CHLORIDE POLYMERS | LABAZ (FR) | 1977-11-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175031-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | MST1, MST1R, MSTN | TSHR 1312/4885THRB 238/4885PTPN7 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.